Gerald Ford’s teenage son Steven once sneaked twenty friends to party at the White House and ordered food and drinks, assuming they were free. The next day, his father showed him the bill from the Oval Office and he learned it came out of his salary
Steven Ford was a teenager living in the White House when his father, Gerald Ford, had just taken office in the mid 1970s.
To him, it did not feel like a government building. It felt like home.
So he treated it like one.
At one point, he invited about twenty friends over to the private residence on the third floor and threw a party. Food and drinks were ordered, brought up, and passed around like it was just part of living there.
Because in his mind, it was.
“I thought food and drink were just part of the perks of living at the White House,” he later admitted.
The next day, reality caught up with him.
He got a message from his father’s secretary. The president wanted to see him. Not later. Now.
He walked into the Oval Office and found his father holding a small pink receipt.
No speech. No lecture.
Just the bill.
That was the moment it clicked. The food, the drinks, all of it, was not free. It came out of the president’s personal funds. Out of his salary.
“I didn’t know it came out of his salary,” Steven said.
And that part surprises a lot of people.
The White House is provided by the government. The staff is paid for. State dinners, official events, and diplomatic functions are covered because they are part of the job. The president also receives a salary, along with allowances for travel, security, and certain official expenses.
But the private side of life inside the White House works differently.
Groceries, casual meals, dry cleaning, personal toiletries, and anything considered non official are billed directly to the first family. The kitchen keeps track. The residence staff keeps track. Every snack, every soda, every late night order shows up on a bill.
There is no blank check.
Presidents have talked about this openly over the years. Barack Obama once joked that he had to pay for his own toothpaste. Bill Clinton reportedly ran up significant food bills during his time in office. Even something as simple as a guest staying overnight can come with added costs.
The perks are real, but they are specific.
You get the house. You get the staff. You get the platform and the power.
But if you order pizza for twenty friends, you are still paying for the pizza.
For Steven Ford, that lesson came in the form of a pink receipt, handed to him by his father in the Oval Office.
Harry Markopolos determined Bernie Madoff was a fraud within five minutes of review. He then spent 10 unsuccessful years trying to alert the SEC.
Harry Markopolos did not need a team, a task force, or a decade of forensic accounting to spot something was wrong with Bernie Madoff. He needed about five minutes.
That is not an exaggeration. Markopolos, a financial analyst with a background in derivatives, was handed Madoff’s returns and asked a simple question: Could you replicate this strategy? What he found instead was something far more unsettling. The numbers did not just look impressive. They looked impossible.
Madoff claimed to be using a split strike conversion strategy, a legitimate options trading method. But Markopolos quickly realized the math did not add up. The returns were too consistent. Too smooth. Markets do not behave like that. Even the best strategies have volatility, bad months, stretches of underperformance. Madoff’s fund looked like it had been scrubbed clean of reality.
Markopolos tried to reverse engineer the trades. He checked options volumes. He compared Madoff’s supposed activity to what was actually happening in the market. There simply was not enough trading volume to support the scale of Madoff’s operation. It was like someone claiming to have drained a lake using a teaspoon while the lake was still full.
So Markopolos did what you would expect someone to do when they uncover what might be the largest financial fraud in history. He went to the regulators.
Specifically, the U.S. Securities and Exchange Commission.
And then he kept going back.
And back.
And back again.
Over the course of nearly a decade, Markopolos submitted detailed complaints, complete with mathematical proofs, industry analysis, and blunt conclusions. At one point, he titled a report The World’s Largest Hedge Fund is a Fraud. He was not being subtle.
But nothing happened.
The SEC either did not understand the complexity of what Markopolos was showing them, did not prioritize it, or simply failed to connect the dots. Different offices handled different pieces. Investigations were opened and closed without meaningful action. Meanwhile, Madoff continued to operate, pulling in billions from investors who believed they had found something safe, steady, and elite.
Markopolos later described his experience as shouting into the void. He was not ignored because he was unclear. He was ignored because the system was not built to handle someone like him. He was an outsider, not part of the inner financial circle. And he was telling a story that, if true, would imply a catastrophic failure of oversight.
It was not until the 2008 financial crisis that the whole thing finally unraveled. Investors, desperate for cash, began asking for their money back. The illusion could not hold. In December 2008, Madoff confessed to his sons, who turned him in. The Ponzi scheme worth an estimated 65 billion dollars on paper collapsed almost overnight.
Markopolos had been right the entire time.
A boy who got his own NASA space suit. He lived in a bubble for all his life since he had a disease that left him defenseless against germs. The suit allowed him to go outside and play. And although the procedure to put it on was complicated, he could finally go and learn with kids his age
The boy became known to the world as the “Bubble Boy,” but his real name was David Vetter.
From the moment he was born, his life was defined by something most people never have to think about: the invisible world of germs. David had a rare condition called Severe Combined Immunodeficiency, or SCID. His immune system did not work. A common cold, something most kids shake off in a few days, could have killed him.
So he lived inside a sterile plastic bubble.
Everything that entered that environment had to be carefully cleaned and prepared. Food, toys, books, even the air itself was controlled. Physical contact with other people was not possible. No hugs. No playing outside. No sitting in a classroom with other kids.
It was a life measured in inches of plastic.
But David was still a child. Curious and restless, wanting to move and explore.
That is where NASA stepped in.
Engineers who were used to designing suits for astronauts created a specialized suit that functioned like a portable version of his bubble. It kept him sealed off from harmful bacteria while allowing him to step outside.
Putting it on was complicated. The suit had to be connected carefully, sealed perfectly, and checked repeatedly. Any mistake could be dangerous.
But once he was inside it, he could move through the world instead of watching it from behind a barrier. He could walk outside, touch things, and interact in ways that had never been possible before.
As he grew older, doctors attempted a bone marrow transplant in hopes of curing his condition. The donor was his sister, and at the time, it seemed like his best chance at a normal life.
Unbeknownst to doctors, the marrow carried a dormant Epstein Barr virus infection. Because David had no functioning immune system, his body could not fight it.
The virus led to an aggressive lymphoma.
After the transplant, for the first time in his life, David was briefly removed from the bubble. But his condition rapidly deteriorated. In 1984, at the age of 12, David Vetter died from complications related to the infection.
In the 80’s Bayer sold contaminated blood products after safer versions became available. Although the product was tainted with HIV, a concern discussed by Bayer and the FDA, there was an impression of protecting the companies’ profits at the cost of infecting large numbers of people with HIV. Once it was discovered in the US, they continued to sell it overseas for over a year in order to clear stock.
In the early 1980s, a quiet crisis was unfolding inside hospitals and clinics, one that would only fully come into focus years later.
At the center of it was Bayer and its Cutter Biological division, which produced a blood clotting product used by people with hemophilia. For patients with this condition, these treatments were not optional. They were life sustaining, allowing them to control bleeding that could otherwise be fatal.
The problem was how those products were made.
At the time, clotting factors were derived from pooled human plasma, meaning blood from thousands of donors was combined into a single batch. This made the supply efficient, but it also meant that if even one donor carried a bloodborne virus, the entire batch could become contaminated.
By the early 1980s, as the HIV AIDS crisis was beginning to emerge, researchers and health officials were increasingly concerned that the virus could be transmitted through blood products. Evidence was mounting. The risk was not theoretical.
Around this same time, a safer method was developed by heat treating the clotting factor to inactivate viruses.
Documents and later investigations showed that there were internal discussions within Cutter and awareness among regulators, including the U.S. Food and Drug Administration, about the potential dangers of the older untreated product. The heat treated version was becoming available and was understood to be significantly safer.
Yet the transition was not immediate.
For a period of time, the older non heat treated product continued to be distributed. In the United States, concerns and pressure eventually led to recalls and a shift toward the safer version. But overseas, particularly in parts of Asia and Latin America, the older product remained on the market.
Shipments continued.
Internal communications that later surfaced suggested a focus on managing inventory and avoiding financial losses from unsold stock. Rather than discarding the remaining supply of a potentially dangerous product, it was sold in markets where regulatory pressure was lower and awareness was still developing.
The result was devastating.
Thousands of people with hemophilia around the world were infected with HIV through contaminated blood products. Many of them were children. Families who relied on these treatments in good faith found themselves facing a completely different and far more deadly disease.
In the years that followed, lawsuits, investigations, and public outrage exposed how decisions had been made and what was known at the time. The scandal became one of the most infamous examples of the intersection between corporate decision making, public health, and ethics.
If under-cooked, a popular mushroom in China causes “lilliputian hallucinations,” a rare phenomenon involving miniature human or fantasy figures. The hallucinations are consistent across people and cultures: “tiny, elflike people” climbing under doors, scaling walls & clinging to furniture
Every summer in China’s Yunnan province, something strange keeps happening.
People show up at hospitals describing the same thing. Not general confusion. Not vague hallucinations. Something far more specific.
They are seeing tiny people.
Small, elflike figures moving through their homes. Marching under doors. Climbing walls. Hanging off furniture like it all belongs to them.
For years, health officials investigated these cases and traced them back to a local delicacy: a wild mushroom called Lanmaoa asiatica.
It is widely eaten in the region and known for its rich, savory flavor. But locals also know something else. If you do not cook it thoroughly, it can cause intense and highly unusual hallucinations.
Scientists call this phenomenon Lilliputian hallucinations.
What makes it remarkable is not just the vividness, but the consistency. Across different people, backgrounds, and even countries, the hallucinations follow the same pattern. Tiny humanlike figures behaving in coordinated, almost purposeful ways.
This is not the typical psychedelic experience.
The active compound in this mushroom is not psilocybin, the substance most commonly associated with psychedelic mushrooms. The effects also take much longer to appear, sometimes 12 to 24 hours after consumption, and can last long enough to require hospitalization and monitoring.
That delay alone makes it impractical as a recreational drug. There is no known culture that uses it intentionally for its hallucinogenic effects.
Biologist Colin Domnauer decided to take a closer look at the mystery after interest in the cases had faded. He visited mushroom markets in Yunnan and asked vendors a simple question: which mushroom is responsible for making people see tiny figures?
The answer was consistent.
Lanmaoa asiatica.
Genetic testing confirmed the identification, and laboratory studies showed that extracts from the mushroom caused significant behavioral changes in animals. Domnauer also identified similar specimens in the Philippines, suggesting the mushroom and its effects may be more widespread than previously understood.
Earlier reports from places like Papua New Guinea had been dismissed as cultural myth, largely because the species had not yet been formally identified. It was not officially described until 2015, which meant researchers at the time were effectively looking for something they did not yet know how to name.
What remains unclear is how this mushroom produces such specific and repeatable hallucinations.
Why tiny people?
Why the same movements, the same behaviors, across completely different individuals?
Those questions are still unanswered. But whatever the mechanism is, it offers a rare window into how the brain constructs reality and how certain compounds can disrupt it in oddly precise ways.
Related Posts:
